Objective : Data regarding the clinical characteristics of COVID-19 infection MESHD is rapidly accumulating. However, most studies thus far are based on hospitalized patients and lack longitudinal follow up. As the majority of COVID-19 cases are not hospitalized, prospective studies of symptoms in the population presenting to primary care are needed. Here, we assess the longitudinal dynamic of clinical symptoms in non-hospitalized individuals prior to and throughout the diagnosis of SARS-CoV-2 infection MESHD. Design Data on symptoms were extracted from electronic health records (EHR) consisting of both results of PCR tests and symptoms recorded by primary care physicians, and linked longitudinal self reported symptoms. Setting The second largest Health Maintenance Organization in Israel , Maccabi Health Services Participants From 1/3/2020 to 07/06/2020, information on symptoms from either surveys or primary care visits was available for 206,377 individuals, including 2,471 who tested positive for COVID-19. Main Outcomes Longitudinal prevalence SERO of clinical symptoms in COVID-19 infection MESHD diagnosed by PCR testing for SARS-CoV-2 from nasopharyngeal swabs. Results: In adults TRANS, the most prevalent symptoms recorded in EHR were cough MESHD cough HP (11.6%), fever MESHD fever HP (10.3%), and myalgia MESHD myalgia HP (7.7%) and the most prevalent self-reported symptoms were cough MESHD cough HP (21%), fatigue MESHD fatigue HP (19%) and rhinorrhea HP and/or nasal congestion (17%). In children TRANS, the most prevalent symptoms recorded in the EHR were fever MESHD fever HP (7%), cough MESHD cough HP (5.5%) and abdominal pain MESHD abdominal pain HP (2.4%) . Emotional disturbances were documented in 15.9% of the positive adults TRANS and 4.2% of the children TRANS. Loss of taste and smell, either self-reported or documented by a physician, 3 weeks prior to testing, were the most discriminative symptoms in adults TRANS (OR =11.18 and OR=5.47 respectively). Additional symptoms included self reported headache MESHD headache HP (OR = 2.03) and fatigue MESHD fatigue HP (OR = 1.73) and a documentation of syncope MESHD syncope HP, rhinorrhea HP (OR = 2.09 for both ) and fever MESHD fever HP (OR= 1.62 ) by a physician. Mean time to recovery TRANS was 23.5 +- 9.9 days. Children TRANS had a significantly shorter disease MESHD duration (21.7 +- 8.8 days, p-value=0.01). Several symptoms, including fatigue MESHD fatigue HP, myalgia MESHD myalgia HP, runny nose and shortness of breath were reported weeks after recovery. Conclusions As the COVID-19 pandemic progresses rapidly worldwide, obtaining accurate information on symptoms and their progression is of essence. Our study shed light on the full clinical spectrum of symptoms experienced by infected individuals in primary care, and may alert physicians for the possibility of COVID-19 infection MESHD.